Invest before our planned Nasdaq listing under MXRX

Med-X, Inc. Launches Regulation A+ Public Offering to Advance Scientifically Validated, Eco-Friendly Professional Pest Control and Pain Management Solutions

NASDAQ Here We Come. Meet MXRX.

We’re planning a direct listing on the Nasdaq, and we’ve already reserved the ticker symbol "MXRX.” This is a rare opportunity to invest before it happens.

Sign Up For Company Updates

Your Email
Submission received! Check your inbox for the Med-X updates.
Oops! Something went wrong while submitting the form.

LOS ANGELES – May 30, 2025 — Med-X, Inc., a leading pioneer of eco-friendly pest control and wellness solutions, announces the launch of a Regulation A+ equity financing round, aiming to raise up to $10 million through the sale of common stock at $4.00 per share with a $600 minimum. This public offering is open to most individuals aged 18 and over, providing an opportunity to invest directly in Med-X via the company's crowdfunding portal (the “Public Offering”).

At the forefront of Med-X's multiple product offerings is the flagship product line Nature-Cide, an eco-friendly pest control solution derived from various natural essential oils. The ingredients in Nature-Cide formulations have been scientifically recognized for their insecticidal properties. A 2019 non-sponsored study published in the Florida Journal of Mosquito Control found that a Nature-Cide formulation containing clove and cottonseed oils was more effective against adult mosquitoes than three synthetic pyrethroid-based chemical products that are commonly used by professional pest control applicators for mosquito control globally.

Further research underscores the efficacy of these types of essential oils in pest managementoperations. A 2024 article in the journal Agriculture highlights the biocidal, repellent, and antifeedant effects of essential oils, noting their potential as natural alternatives to synthetic pesticides. Med-X is strategically positioned at the intersection of rising consumer demand for sustainable and chemical-free solutions in industries ranging from professional pest control and agriculture to public health and disaster relief. The Nature-Cide product line offers unique proprietary, minimum-risk pesticide solutions that are state EPA-registered and widely adopted by professionals and consumers alike. With a variety of verified consumer reviews on Amazon Prime, the brand continues to demonstrate a broad and strong product-market fit.

Med-X continues to expand Nature-Cide's global footprint, with recent product placements in Thailand, Singapore, and New Zealand. The company is actively pursuing registrations in multiple Asian countries, Australia, the UAE, Saudi Arabia, and South America – collaborating with international distributors such as Ensystex and Anasac. In North America, distribution partnerships with Target Specialty Products, Veseris, and Site-One are helping to facilitate future market penetration in Canada, the Caribbean, and Central America.

CEO Matthew Mills emphasizes that the Regulation A+ public offering should enable Med-X to accelerate growth and pursue a direct listing on a national stock exchange, with aspirations to join the NASDAQ under the reserved symbol "MXRX." The Company plans to engage with the investment community through presentations at various investor conferences, supported by strategic partnerships with investor relations firm MZ Group and investment bank Maxim Group.

Med-X remains committed to delivering sustainable, long-term value to shareholders by advancing natural, scientifically supported pest control pain management solutions that prioritize safety and environmental responsibility as well as sustainability.

About Med-X, Inc.

Med-X, Inc. is an innovator in minimum-risk pest control and wellness products, dedicated to developing safe, effective, and environmentally friendly solutions. The company's flagship Nature-Cide products are designed to be safe for use around people, pets, and the environment when used as directed. They are free from harmful synthetic chemicals, offering a responsible and sustainable choice for pest control in residential, commercial, and agricultural settings. The products are also non-flammable and manufactured in the USA, adhering to stringent quality controls.

For more information, please visit www.medx-rx.com.

Investor Relations Contact:

Lucas Zimmerman
Managing Director
MZ Group - MZ North America
262-357-2918
MXRX@mzgroup.us

FAQs

Where can I find more information on Med-X?

You can review all of Med-X’s SEC Filings, including the offering circular for the Regulation A+ offering, here.

What is the offering Price?

The offering price is $4 per share and the minimum investment amount for this round is $600.

How and when can I access the subscription document and invest?

Click “Invest Now” anywhere on this site, or follow this link: invest.medx-rx.com/checkout. You will be directed to view the subscription agreement and complete an investment.

What payment options are available?

Investors can purchase shares via credit card, bank-to-bank payments, or express wires (reconciled in real-time).

Do I need to be an accredited investor?

This offering is open to both accredited and non-accredited investors. If you are a non-accredited investor, please note that you cannot invest more than 10% of the greater of your annual income or net worth.

What is an accredited investor? 

According to the SEC, an individual accredited investor can be defined as the following:  

An accredited investor, in the context of a natural person, includes anyone who: 

  • earned income that exceeded $200,000 (or $300,000 together with a spouse or spousal equivalent) in each of the prior two years, and reasonably expects the same for the current year, OR 
  • has a net worth over $1 million, either alone or together with a spouse or spousal equivalent (excluding the value of the person’s primary residence), OR 
  • holds in good standing a Series 7, 65 or 82 license. 

Additionally, an accredited investor as an entity can be defined as the following: 

  1. A trust is considered to be an accredited investor if its assets exceed $5 million, it is not created to purchase the securities and it is directed by a sophisticated person; or 
  1. An entity is an accredited investor if its investment exceeds $5 million and it is not created to purchase securities. 
  1. An entity in which all equity owners are accredited investors. 
Why did my payment get rejected? What can I do to resolve this?

If your credit card payment was declined, please call your credit card provider to pre-authorize the transaction. Additionally, if your bank-to-bank transfer via ACH has failed, it is recommended that you contact your bank for more information.

How can I change the email address associated with my account?

To change your email address, please navigate to the top-right corner of your Dashboard. Within your profile settings, you can change the email address associated with your account. If you would like to merge investments to a pre-existing account, under a different email address, please contact info@dealmaker.tech for assistance. Please specify the applicable email addresses to be changed. For investor security, you will be asked to verify that you have access to the applicable accounts.

How can I invest as a trust or corporation?

You can specify whether you are investing as an individual, or as a corporation/trust/custodial. Upon selecting any of the non-individual options, you will be prompted to enter relevant information and populate your subscription agreement accordingly.

What happens after I complete the online investment process?

1) Funding Processed:  

Your investment funding status will update upon receipt of your funds. If paying by bank-to-bank transfer, your payment will initially appear as pending, and will either clear or fail within five business days. If paying by wire domestically, your wire should be reconciled within one business day. International wires vary. Once funds are received, it can take approximately 1-2 weeks.

2) Identity Processed: 

In some instances, we may reach out to you requesting additional information in order to verify your identity & finish processing your investment, which may increase the overall processing time. 

3) Subscription Confirmation: 

Once your investment has been fully processed and confirmed, you will receive a notification when your subscription agreement has been accepted. Subsequently, you will receive a digital confirmation of the security holdings. If 3 weeks pass by and you do not receive any information from us, please email us at investorrelations@medx-rx.com We may still require additional information. We recommend you check your spam folder first for any email communications! 

‍

Will I receive a paper share certificate?

Please note that if your securities are being distributed through the DealMaker platform, you will receive a digital certificate or DRS statement from the transfer agent, uploaded to your investment portal. No paper share certificates are distributed via DealMaker.  

‍

For further information regarding DRS statement distribution, please contact our investor support team at: investorrelations@medx-rx.com.

‍

I would like to speak to someone about my investment, who can I contact? 

For more information regarding your investment in this offering, please contact our investor support team at: investorrelations@medx-rx.com

I haven’t found the answer to my question. Where can I look next? 

You can search the DealMaker knowledge base for more information here, or contact investor support at investorrelations@medx-rx.com.

Can I transfer my shares? 

Yes. Securities sold in a Regulation A+ offering are not considered “restricted securities” under Securities Act Rule 144. As a result, sales of securities by persons who are not affiliates of the issuer are not subject to any transfer restrictions.

‍

Investors need to check with a brokerage account representative to determine whether their provider will allow for the securities to be (i) directly deposited to a brokerage account or (ii) transferred into such account at a later day. The policies may vary between different providers. 

‍

Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.

Submission received! Check your inbox for the Med-X updates.
Oops! Something went wrong while submitting the form.